Search
for
Sort by
Research 61–90 of 82
- Refractory Myasthenia Gravis and Concurrent Alopecia Areata Postthymectomy With Improvements After Cortisone Taper: A Case Report
- Atypical Presentation of Lichen Planopilaris: Presentation of Two Cases and Review
- Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea
- Cocaine-related bullous disease
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Postępowanie kosmetologiczne w wybranych jednostkach chorobowych : podręcznik dla studentów kosmetologii oraz kierunków medycznych
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- 公表学術論文等リスト 2018
- Natural Killer Group 2 Type D (NKG2D) Gene Polymorphism in Systemic Lupus Erythematosus-Suez Canal Region - Egypt
- Minireview: vitamin D receptor: new assignments for an already busy receptor. - eScholarship
- A case of systemic lupus erythematosus complicated with aortic regurgitation due to bacterial endocarditis
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Gloriosa superba poisoning mimicking an acute infection- a case report
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Folliculitis decalvans: a case report of satisfactory recovery after implementing isotretinoin therapy
- Creatine phosphokinase levels and isotretinoin therapy
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- G588(P) Transient renal and hepatic dysfunction in severe profound hypothyroidism
- Clinical Manifestations of Dermatomyositis
- 원저 : 피부근염의 임상적 고찰
- Haff disease associated with the ingestion of the freshwater fish Mylossoma duriventre (pacu-manteiga)
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review